MediciNova, Inc. (MNOV)
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States.
It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction.
The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers.
It has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.
|IPO Date||Feb 8, 2005|
|CEO||Dr. Yuichi Iwaki M.D., Ph.D.|
4275 Executive Square, Suite 300
La Jolla, California 92037
|Fiscal Year||January - December|
|Dr. Yuichi Iwaki M.D., Ph.D.||Co-Founder, President, Chief Executive Officer and Executive Director|
|Dr. Kazuko Matsuda M.D., M.P.H., MPH, Ph.D.||Chief Medical Officer and Director|
|Jason J. Kruger CPA||Chief Financial Officer and Principal Financial Officer|
|Dr. David H. Crean M.B.A., Ph.D.||Chief Business Officer|
|John O'Neil CPA||Controller|
Latest SEC Filings
|Nov 9, 2023||10-Q||Quarterly Report|
|Aug 9, 2023||10-Q||Quarterly Report|
|Aug 7, 2023||8-K||Current Report|
|Jun 22, 2023||8-K||Current Report|
|Jun 14, 2023||8-K||Current Report|
|May 11, 2023||10-Q||Quarterly Report|
|Apr 26, 2023||8-K||Current Report|
|Apr 26, 2023||ARS||Filing|
|Apr 26, 2023||DEFA14A||Additional definitive proxy soliciting materials and Rule 14(a)(12) material|
|Apr 26, 2023||DEF 14A||Other definitive proxy statements|